Ascletis Oral GLP-1 ASC30 Hits Phase II Diabetes Endpoint as Phase III Obesity Program Advances
Ascletis' oral GLP-1 ASC30 met its Phase II type 2 diabetes primary endpoint with 1.6%–1.7% placebo-adjusted HbA1c reductions, while Phase III obesity trials continue.
Read article →